Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Proligo Expands into Genopole® d'Evry Biopark

Published: Friday, October 20, 2006
Last Updated: Friday, October 20, 2006
Bookmark and Share
Sigma-Proligo provides researchers with high-quality oligonucleotides due to a high throughput synthesis platform.

Sigma-Proligo, a division of the Sigma-Aldrich group has announced it has acquired 2,000 sq. meters of office space in the heart of the Genopole® d'Evry biopark in the region of Paris. The official inauguration has took place on October 19 at 11:30 a.m.

Sigma-Proligo provides researchers throughout the world with high-quality oligonucleotides due to a high throughput synthesis platform.

With 65 employees in France, the majority of whom are researchers, Sigma-Proligo has expertise in nucleic acid synthesis and holds several key patents in siRNA gene silencing technology.

The new facility is expected to provide the capacity needed for the Company to advance the production of high-quality oligonucleotides in order to meet emerging needs within the bioscience research sector.

Sigma-Proligo develops protocols and methods in the field of oligonucleotides, and is one of four companies with the MIT license on siRNAs.

"The 'biotech' image of Genopole, as well as the offices and working environment perfectly adapted to our operations, have been the main reasons behind our expansion into Evry," said Khalil Arar, operations manager of Sigma-Aldrich Evry.

"The RNAi market has a predicted compound annual growth rate of 14%, and these new facilities are expected to provide Sigma-Proligo with the capacity to meet the increasing market demand for RNAi products."

"The facilities should also enable the Company to continue to supply customers with innovative products."

Thierry Mandon, President of Genopole, said, "A mature company moving onto the campus boosts the attractiveness of Evry-Corbeil as a business location, and demonstrates its credibility in the biotech sector."

Pierre Tambourin, CEO of Genopole, added, "This move will promote interactivity with our start-ups, which will profit from Sigma Proligo's knowledge, and our larger companies who need dynamic local links in order to pursue their development."

Marc Rebois, Director of SEM Genopole, the company that creates and manages the site's real estate and business accommodation resources, added, "Welcoming such a well-known company to Evry-Corbeil is a reward for our ongoing focus on truly biotech-dedicated real estate solutions, and it also constitutes recognition of our campus on the international level."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
Sigma Life Science announces that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011.
Thursday, February 03, 2011
Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Company’s CompoZr® cell lines ranked second as The Scientist magazine unveils this year’s best life science innovations.
Monday, December 06, 2010
Sigma® Life Science Enters Genetically Modified Cell Market
Sigma Life Science launches range of engineered cell lines exploiting CompoZr® zinc finger nuclease technology.
Monday, September 06, 2010
Sigma® Life Science and Switchgear Genomics to Co-Develop Simplified Novel MicroRNA Target Validation System
SwitchGear Genomics and Sigma’s lentiviral technology combined to simplify miRNA target validation, enabling researchers to investigate gene regulation.
Tuesday, August 10, 2010
Sigma-Aldrich Announces Service Provider for WGA Technology
Sigma announces MOgene as its first service provider of the GenomePlex® Whole Genome Amplification technology.
Wednesday, May 31, 2006
Sigma-Aldrich Sponsors Full-Text Article on High Content Viral Library Screens
The authors reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 27, 2006
Sigma-Aldrich Expands Position in Whole Genome Amplification
Sigma-Aldrich enters licensing agreement to offer GenomePlex® Whole Genome Amplification kits to service providers.
Monday, February 20, 2006
Sigma-Aldrich Names Jai Nagarkatti as Chief Executive Officer
The appointment will be effective on January 1, 2006.
Wednesday, November 09, 2005
Sigma Granted Patent for REDTaq™ DNA Polymerase Product Line
REDTaq™ products are a blend of various DNA polymerases combined with an inert red dye that allows quick visual confirmation of enzyme addition and reaction homogeneity.
Friday, September 16, 2005
Sigma-Aldrich Launches Online STAIN EXPERT™ Application
A Flash Platform is designed to guide customers through a wide range of staining procedures while reducing the complexity of multi-step processes.
Thursday, September 08, 2005
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Unexpected Epigenetic Enzymes Role in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Tissue Damage Is Key for Cell Reprogramming
Researchers have shown tissue damage is important for cells to return to an embryonic state for cell reprogramming.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!